AMAG Pharmaceuticals (AMAG) Posts Narrower than Expected Q2 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts AMAG Hot Sheet
Price: $13.75 --0%
Financial Fact:
Research and development expenses: 17.12M
Today's EPS Names:
SFBC, KSBI, PVBK, More
Financial Fact:
Research and development expenses: 17.12M
Today's EPS Names:
SFBC, KSBI, PVBK, More
Join SI Premium – FREE
AMAG Pharmaceuticals (NASDAQ: AMAG) reported Q2 loss of ($0.92), $0.14 better than the analyst estimate of ($1.06). Revenue for the quarter came in at $15.4 million versus the consensus estimate of $14.8 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Orion Marine Group (ORN) Tops Q3 EPS by 3c ; Offers Guidance
- Rogers (ROG) Tops Q3 EPS by 20c, Misses on Revenue; Offers Q4 Guidance
- Ks Bancorp, Inc. (KSBI) Tops Q3 EPS by 258c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
